BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19244476)

  • 1. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
    Ganapathi SB; Kester M; Elmslie KS
    Am J Physiol Cell Physiol; 2009 Apr; 296(4):C701-10. PubMed ID: 19244476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular determinants of R-roscovitine block of hERG channels.
    Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
    PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
    Guo J; Gang H; Zhang S
    J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
    Luo T; Luo A; Liu M; Liu X
    Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
    Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel.
    Su Z; Martin R; Cox BF; Gintant G
    J Mol Cell Cardiol; 2004 Jan; 36(1):151-60. PubMed ID: 14734057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolutionarily conserved residue A653 plays a key role in HERG channel closing.
    Stepanovic SZ; Potet F; Petersen CI; Smith JA; Meiler J; Balser JR; Kupershmidt S
    J Physiol; 2009 Jun; 587(Pt 11):2555-66. PubMed ID: 19406877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
    Park SJ; Kim KS; Kim EJ
    J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
    Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
    J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramide modulates HERG potassium channel gating by translocation into lipid rafts.
    Ganapathi SB; Fox TE; Kester M; Elmslie KS
    Am J Physiol Cell Physiol; 2010 Jul; 299(1):C74-86. PubMed ID: 20375276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
    Zhao J; Lian Y; Lu C; Jing L; Yuan H; Peng S
    J Ethnopharmacol; 2012 Jun; 141(2):685-91. PubMed ID: 21920426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
    Thurner P; Stary-Weinzinger A; Gafar H; Gawali VS; Kudlacek O; Zezula J; Hilber K; Boehm S; Sandtner W; Koenig X
    J Pharmacol Exp Ther; 2014 Feb; 348(2):346-58. PubMed ID: 24307198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation.
    Yarotskyy V; Elmslie KS
    J Pharmacol Exp Ther; 2012 Feb; 340(2):463-72. PubMed ID: 22088954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
    DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
    J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
    Zhao J; Wang Q; Xu J; Zhao J; Liu G; Peng S
    Eur J Pharmacol; 2011 Jun; 660(2-3):259-67. PubMed ID: 21497594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The calmodulin inhibitor N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide directly blocks human ether à-go-go-related gene potassium channels stably expressed in human embryonic kidney 293 cells.
    Zhang XH; Jin MW; Sun HY; Zhang S; Li GR
    Br J Pharmacol; 2010 Oct; 161(4):872-84. PubMed ID: 20860665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
    Milnes JT; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
    Br J Pharmacol; 2003 Jul; 139(5):887-98. PubMed ID: 12839862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.